No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
CFO Cashes In: Protagonist Therapeutics Stock Sale Shakes Market!
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study With Rusfertide at ASCO 2025
Protagonist Therapeutics Reports Granting of Inducement Award
Jefferies Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $68
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $80
Protagonist Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.